I have covered the novel androgen receptor antagonist Breezula® (Clascoterone) for 11 years across numerous posts. The product was originally known as CB-03-01, and manufactured by a company named Cassiopea (Italy). The latter was acquired by Cosmo Pharmaceuticals (Ireland) in December 2021. Clascoterone 5% is expected to get approved in the US and EU as a topical hair loss product in 2027. If successful, it will only be the third ever hair loss product approved in the US after Minoxidil (1988) and Finasteride (1997).
Update: April 15, 2026
Positive 12-Month Phase III Trial Results of 5% Topical Clascoterone
Cosmo Pharmaceuticals just announced positive 12-month Phase III results for its Clascoterone 5% topical solution in treating men with mild-to-moderate androgenetic alopecia (AGA). Key points:
- Patients who remained on Clascoterone treatment through month 12 continued to gain hair. In contrast, patients who switched to the placebo from month 7 onwards experienced a reduction in prior gains.
- Patients who remained on Clascoterone for the full 12 months achieved a 2.39x improvement in Target Area Hair Count (TAHC) versus patients who received Clascoterone for 6 months and then switched to vehicle from month 7 to month 12.
- The Phase III trial was composed of SCALP 1 and SCALP 2 pivotal studies. It enrolled 1,465 subjects across 51 centers in the United States and Europe. This made it the largest Phase III clinical program ever conducted for a topical male AGA treatment.
- Patient-reported outcomes were also positive. Subjects treated with Clascoterone for 12 months reported a +24.5% relative improvement in treatment satisfaction versus vehicle groups.
- Cosmo plans to file for a New Drug Application (NDA) with the US FDA in early 2027. They will also file a Marketing Authorization Application (MAA) in Europe.
This development also bodes favorably for China-based Kintor Pharma’s androgen receptor antagonist KX-826 (Pyrilutamide). It is currently in Phase 3 trials. A number of other such products are currently in trials or have been released as weaker cosmeceuticals.
December 2, 2025
Cosmo Pharmaceuticals Announces Breakthrough Phase III Trial 6-Month Results for Breezula (Clascoterone)
Earlier today, Cosmo Pharmaceuticals announced breakthrough Phase III trial 6-month topline results for Clascoterone 5% solution in treating male pattern hair loss (androgenetic alopecia). Subsequently, the company’s CMOPF stock price rose a significant 24%.
Interestingly, Cosmo did not use the word “Breezula” even once in the press release. It does not show up on the company’s pipeline page either. And the Breezula page on their site is not working at present. I really hope they do not change the name yet again. My blog post “categories” about this company and product are already too numerous. Cosmo also has a brand new upgraded website with a new domain name.
Key notes from the press release:
- A massive 1,465 patients were randomized into the two identical clinical studies: Scalp 1 (NCT05910450) and Scalp 2 (NCT05914805). I covered these in detail here and here.
- Both studies reached statistically significant endpoints in Target-Area Hair Count (TAHC). The first reached 539% relative improvement compared to placebo; and the second reached 168% relative improvement to placebo.
- The safety profile across both studies for positive.
The way they present these numbers is a bit strange and may exaggerate the efficacy. And the large gap between 539% and 168% is very surprising. In the successful 6-month interim Phase 2 trial results that were presented in 2018, they chose to compare Breezula results with finasteride.
Cosmo will complete the required 12-month safety follow-up in spring 2026. Thereafter, Cosmo plans to promptly pursue parallel regulatory submissions in the United States and Europe.
“Clascoterone 5% topical solution is positioned to become the first topical androgen receptor inhibitor ever approved for AGA, subject to regulatory authorization.”
On a related note, Cosmo Pharma released Winlevi Clascoterone 1% cream in 2020, and it has since become the number 1 most prescribed topical acne brand in the US. Some people were trying to use Winlevi off-label on their scalps in the past, but I suspect that the dose is too low. Moreover, scalp absorption of the cream might be totally different from scalp absorption of the solution.
Also of interest, an August 2025 study concluded that Breezula promotes dermal papilla inductivity and hair matrix keratinocyte proliferation to a similar extent as minoxidil. In addition, Breezula also reduces the secretion of hair growth inhibitor IL-6 in balding skin samples. Some of the scientists involved in this research are affiliated with Cosmo.
Years ago, I mentioned how a hair transplant surgeon raved to me about Breezula based on a presentation (with photos) that he witnessed at an ISHRS conference. Fingers crossed that we finally have a third FDA-approved hair loss treatment by the end of 2027 (30 years after finasteride was approved, and 39 years after minoxidil was approved)!
